Dr. Amy Pasternak earned her PharmD from the Ohio Northern University Raabe College of Pharmacy in 2014. After graduation, she completed a PGY-1 Pharmacy Practice Residency at Cleveland Clinic Hillcrest Hospital in Mayfield Heights, OH. She then pursued specialty training in clinical pharmacogenetics as the PGY-2 Clinical Pharmacogenetics Resident at St. Jude Children’s Research Hospital in Memphis, TN, and as a Clinical Pharmacy Translational Fellow at the University of Michigan College of Pharmacy. Dr. Pasternak joined the U-M faculty as a Clinical Assistant Professor in 2018. She became a Board-Certified Pharmacotherapy Specialist in 2015.
Her current clinical practice is focused in the implementation of pharmacogenetics into routine clinical care at Michigan Medicine as part of the pharmacogenetics service. This consult-based service is available to answer patient and clinician questions regarding pharmacogenetics and integrating pharmacogenetic information into the prescribing process through clinical decision support. Dr. Pasternak precepts both APPE and PGY-1 residents on a pharmacogenetics rotation.
Dr. Pasternak’s research focuses on the discovery and validation of pharmacogenetic associations and evaluating the clinical impact of translating pharmacogenetics into patient care. Her current work is focused on increasing the understanding of tacrolimus pharmacogenetic interactions in multiple transplant populations and among routes of administration.
Clinical implementation of pharmacogenetics
Pasternak AL, Kidwell KM, Dempsey JM et al. Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant. Pharmacogenomics. 2019. PMID: 30983501.
Pasternak AL, Zhang L, Hertz DL. CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration. Pharmacogenomics. 2018 Apr;19(6):563-576. doi: 10.2217/pgs-2018-0003. Epub 2018 Apr 9. PMID: 29629825
Pasternak AL, Crews KR, Caudle KE, et al. The impact of the UGT1A1*60 allele on bilirubin serum concentrations. Pharmacogenomics. 2017;18(1):5-16.
Pasternak AL, Link NA, Richardson C, Rose PG. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas. Pharmacotherapy. 2016;36(7):723-30.